Keddy Karen H, Saha Senjuti, Okeke Iruka N, Kalule John Bosco, Qamar Farah Naz, Kariuki Samuel
Tuberculosis Platform, South African Medical Research Council, 1 Soutpansberg Rd, Pretoria, 0001, South Africa.
Child Health Research Foundation, 23/2 Khilji Road, Mohammadpur, Dhaka 1207, Bangladesh.
EBioMedicine. 2021 Nov;73:103668. doi: 10.1016/j.ebiom.2021.103668. Epub 2021 Nov 3.
Despite efforts to reduce the global burden of childhood diarrhoea, 50% of all cases globally occur in children under five years in Low–Income and Middle- Income Countries (LMICs) and knowledge gaps remain regarding the aetiological diagnosis, introduction of diarrhoeal vaccines, and the role of environmental enteric dysfunction and severe acute malnutrition. Biomarkers may assist in understanding disease processes, from diagnostics, to management of childhood diarrhoea and the sequelae to vaccine development. Proteomics has the potential to assist in the identification of new biomarkers to understand the processes in the development of childhood diarrhoea and to aid in developing new vaccines. Centralised repositories that enable mining of large data sets to better characterise risk factors, the proteome of both the patient and the different diarrhoeal pathogens, and the environment, could inform patient management and vaccine development, providing a systems biological approach to address the burden of childhood diarrhoea in LMICs.
尽管人们努力减轻全球儿童腹泻负担,但全球所有腹泻病例中有50%发生在低收入和中等收入国家(LMICs)五岁以下儿童中,在病因诊断、腹泻疫苗的引入以及环境性肠道功能障碍和重度急性营养不良的作用方面仍存在知识空白。生物标志物可能有助于理解疾病过程,从诊断到儿童腹泻的管理以及后遗症,再到疫苗开发。蛋白质组学有潜力协助识别新的生物标志物,以了解儿童腹泻发展过程,并有助于开发新疫苗。能够挖掘大型数据集以更好地表征风险因素、患者和不同腹泻病原体的蛋白质组以及环境的集中式储存库,可以为患者管理和疫苗开发提供信息,提供一种系统生物学方法来应对LMICs儿童腹泻负担。